In 2017, a meta-analysis of 9 RCTs in individuals with and without CVD
Recent cardiovascular
In this meta-analysis on the effects of pioglitazone for secondary prevention of cardiovascular disease (CVD), pioglitazone lowered the risk of recurrent major
However, in 2005, an increased risk of bladder cancer among patients treated with pioglitazone versus placebo was observed in the prospective pioglitazone The consensus is that while pioglitazone reduces the risk of MACE, it has no treatment effect on all-cause mortality while increasing the risk of heart failure hospitalization
However, thiazolidinediones can cause fluid retention thereby increasing the risk of heart failure—a common complication
Consider decreasing insulin dose
Context Pioglitazone is widely used for glycemic control in patients with type 2 diabetes mellitus, but evidence is mixed regarding the influence of medications of this class on cardiovascular outcomes
Abstract
Early use of supplemental insulin, which can potentially increase the risk of hypoglycemia and cardiovascular events, was noted among patients with limited choices
J
Advice for health professionals: cases of cardiac failure have been reported when pioglitazone was used in combination with insulin, especially in patients with risk factors for the development of Background: Studies assessing the efficacy of pioglitazone solely for primary stroke prevention in Asian patients with type 2 diabetes mellitus (DM) and present multiple cardiovascular (CV) risk factors are rare
An increase in risk in the pioglitazone group compared with placebo group was observed for both nonserious and serious fractures
Pioglitazone may increase your risk of serious heart problems, but not treating your diabetes can also damage your heart and other organs
10, 11 In a subsequent meta‐analysis of 19